InVivo Therapeutics Holdings Corp
NVIV
NVIV was delisted on the 12th of February, 2024.
37 hedge funds and large institutions have $15.9M invested in InVivo Therapeutics Holdings Corp in 2017 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 14 closing their positions.
12% less funds holding
Funds holding: 42 → 37 (-5)
36% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 14
46% less capital invested
Capital invested by funds: $29.4M → $15.9M (-$13.4M)
50% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 10
91% less call options, than puts
Call options by funds: $11K | Put options by funds: $117K
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Legal & General Group
London,
United Kingdom
|
+$1.42M |
| 2 |
Millennium Management
New York
|
+$1.15M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$491K |
| 4 |
ECM
Element Capital Management
New York
|
+$382K |
| 5 |
Goldman Sachs
New York
|
+$273K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$3.99M |
| 2 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$987K |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$819K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$601K |
| 5 |
TCIM
TIAA CREF Investment Management
New York
|
-$364K |
NVIV Hedge Fund Activity: Q2 2017 in Review
37 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q2 2017, worth a combined $15.9M — down 46% from $29.4M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of NVIV and 9 opened new positions — a net loss of 5 holders — while 10 trimmed existing stakes and 5 added.
The largest buyer was Legal & General Group, adding an estimated $1.42M. The largest seller was BlackRock, cutting an estimated $3.99M.
- 37 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q2 2017, down from 42 in Q1 2017.
- Funds reported $15.9M of InVivo Therapeutics Holdings Corp stock for Q2 2017, down 46% quarter-over-quarter.
- 9 funds opened new InVivo Therapeutics Holdings Corp positions in Q2 2017 and 14 closed out, a net change of -5 holders.
- The largest InVivo Therapeutics Holdings Corp buyer in Q2 2017 was Legal & General Group, an estimated $1.42M added.
- The largest InVivo Therapeutics Holdings Corp seller in Q2 2017 was BlackRock, an estimated $3.99M sold.
Based on aggregated 13F filings for Q2 2017.